Rosen Law Firm Encourages Soleno Therapeutics Investors to Secure Counsel Before Deadline

Investors who purchased Soleno stock during the Class Period may be eligible for compensation.

Mar. 31, 2026 at 10:29pm

Got story updates? Submit your updates here. ›

Rosen Law Firm, a global investor rights law firm, is reminding purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025 of the important May 5, 2026 lead plaintiff deadline in a securities class action lawsuit. Investors who purchased Soleno stock during this period may be entitled to compensation through a contingency fee arrangement.

Why it matters

The lawsuit alleges that Soleno made false and/or misleading statements about safety concerns related to its drug DCCR, which is being developed to treat hyperphagia in individuals with Prader-Willi syndrome. The lawsuit claims these undisclosed risks could negatively impact DCCR's commercial viability after launch.

The details

The lawsuit alleges that Soleno systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants. As a result, the lawsuit claims the administration of DCCR posed materially greater safety risks than disclosed by Soleno.

  • The Class Period is from March 26, 2025 to November 4, 2025.
  • The lead plaintiff deadline is May 5, 2026.

The players

Rosen Law Firm

A global investor rights law firm that is representing investors in the Soleno Therapeutics securities class action lawsuit.

Soleno Therapeutics, Inc.

A biopharmaceutical company developing DCCR, a drug to treat hyperphagia in individuals with Prader-Willi syndrome.

Got photos? Submit your photos here. ›

What they’re saying

“To join the Soleno class action, go to https://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.”

— Phillip Kim, Esq.

What’s next

Investors have until May 5, 2026 to move the Court to serve as lead plaintiff in the Soleno Therapeutics securities class action lawsuit.

The takeaway

This case highlights the importance for investors to carefully review disclosures from pharmaceutical companies and seek qualified legal counsel if they believe the company has made false or misleading statements that have impacted the stock price.